Best Practice & Research Clinical Rheumatology
Volume 23, Issue 4 , Pages 563-574 , August 2009

Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies

  • Elsa Sousa, MD (Rheumatology Trainee)

      Affiliations

    • Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Hospital de Santa Maria, Av. Professor Egas Moniz, 1649-028 Lisbon, Portugal
    • Corresponding Author InformationCorresponding author. Tel.: +351 21 7999544; Fax: +351 21 799 9412.
    • ,
  • David Isenberg, MD, FRCP, Professor

      Affiliations

    • Centre For Rheumatology Department of Medicine, University College London, London, UK

References 

  1. Moura R, Água-Doce A, Weinmann P, et al. B cells: from the bench to the clinical practice. Acta Reumatol Port. 2008;33:137–154
  2. Hutloff A, Buchner K, Reiter K, et al. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum. 2004;50:3211–3220
  3. Diamanti AP, Rosado MM, Carsetti R, Valesini G. B cells in SLE: different biological drugs for different pathogenic mechanisms. Autoimmun Rev. 2007;7(2):143–148
  4. Gopal A, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med. 1999;134:445–450
  5. Lindholm C, Börjesson-Asp K, Zendjanchi K, et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients refractory systemic lupus erythematosus. J Rheumatol. 2008;35(5):826–833
  6. Leandro M, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673–2677
  7. Leandro M, Cambridge G, Edwards JC, et al. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005;44:1542–1545
  8. Ng KP, Leandro MJ, Edwards JC, et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis. 2006;65(7):942–945
  9. Lu TY-T, Cambridge C, Leandro MJ, et al. A retrospective seven-year analysis of the use of B-cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Care Res, in press.
  10. Jónsdóttir T, Gunnarsson I, Risselada A, et al. Treatment of refractory SLE with Rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008;67(3):330–334
  11. Looney R, Anolik JH, Campbell D, et al. B cell delection as a novel treatment for systemic lupus erythematosus: fase I/II dose –escalating trial of rituximab. Arthritis Rheum. 2004;50:2580–2589
  12. Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B-cell depletion in SLE. Ann Rheum Dis. 2008;
  13. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52(2):501–513
  14. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to convential therapy: a pilot study. Arthritis Res Ther. 2006;8(3):R83
  15. Gunnarsson I, Sundelin B, Jónsdóttir T, et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 2007;56(4):1263–1272
  16. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of Rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66(4):470–475
  17. Lu TY, Jonsdottir T, van Vollenhoven RF, et al. Prolonged B-cell depletion following rituximab therapy in systemic lupus Erythematosus: a report of two cases. Ann Rheum Dis. 2008;67(10):1493–1494
  18. US National Institute of Health . A study to evaluated the efficacy and safety of rituximab in patients with severe systemic lupus erythematosus (EXPLORER). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00137969
  19. Rituxan warning. FDA Consum. 2007;41:3
  20. Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and anti-microbial antibody profiles. Arthritis Rheum. 2006;54:3612–3622
  21. Tahir H, Rohrer J, Bhatia A, et al. Humanized anti- CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford). 2005;44:561–562
  22. Cambridge G, Isenberg DA, Edwards JC, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Arthritis Rheum. 2008;67(7):1011–1016
  23. Jacobi AM, Goldenberg DM, Hiepe F, et al. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis. 2008;67:450–457
  24. Carnahan J, Wang P, Kendall R, et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003;9:3982S–3990S
  25. Dörner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8(3):R74
  26. Gross J, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B cell autoimmune disease. Nature. 2000;404:995–999
  27. Stohl W. SLE: a blys full, yet BAFF disorder. Arthritis Res Ther. 2003;5(3):136–138
  28. Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003;48(12):3475–3486
  29. Ju S, Zhang D, Wang Y, et al. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem. 2006;39(12):1131–1137
  30. Petri M, Stohl W, Chatham W, et al. Association of plasma B Lymphocytes stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;59(8):2453–2459
  31. Furie R, Stohl W, Ginzler E, et al. Safety, pharmacokinetic and pharmacodynamic results of a Phase I single and double dose escalation study of lymphostat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum. 2003;48:S377
  32. Wallace D, Lisse J, Stohl W, et al. Belimumab (Bmab), a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), shows bioactivity and reduces systemic lupus erythematosus disease activity. [abstract] Ann Rheum Dis. 2006;65:62
  33. Furie R, Petri M, Weisman MH, et al. Belimumab (fully human monoclonal antibody to BLyS) improved or stabilized SLE disease activity and reduced flare rate during 3 years therapy. Ann Rheum Dis. 2008;67:53;[abstract OP-0017]
  34. US national Institutes of Health . A study of Belimumab, a fully human monoclonal anti-BLyS antibody in subjects with systemic lupus erythematosus. Available from: http://www.clinicaltrials.gov/ct/gui/show/NCT00410384?order = 1
  35. Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56(12):4142–4150
  36. US national Institutes of Health . Atacicept phase II/III in Generalized Systemic Lupus Erythematosus (April SLE). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00624338?term = atacicept+and+SLE&rank = 1
  37. Ohsugi Y. Recent avances in imunopathophysiology of interleukin-6: innovating therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull. 2007;30(11):2001–2006
  38. Tackey E, Lipsky PE, Illei GG. Rationale for interleukine-6 blockade in systemic lupus erythematosus. Lupus. 2004;13(5):339–343
  39. Grondal G, Gunnarsson I, Ronnelid J, et al. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 2000;18:565–570
  40. Ripley BJM, Goncalves B, Isenberg DA, et al. Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis. 2005;64:849–853
  41. Sun KH, Yu CL, Tang SJ, Sun GH. Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, IL-6, IL-8, IL-10 and TNF alpha from normal human mononuclear cells involving in lupus pathogenesis. Immunology. 2000;99:352–360
  42. Tsai CY, Wu TH, Yu CL, et al. Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm–Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron. 2000;85:207–214
  43. Shirota Y, Yarboro C, Sims G, et al. The impact of in vitro anti-interleukin 6 receptor blockade on circulating T and B-cell subsets in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:S697
  44. Illei G, Yarboro C, Shirota Y, et al. Tocilizumab (Humanized Anti IL-6 Receptor Monoclonal Antibody) in patients with systemic lupus erythematosus (SLE): safety, tolerability and preliminary efficacy. Arthritis Rheum. 2006;54(Suppl.):4043;[Abstract]
  45. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of TNFa blockade in systemic lupus erythematosus – an open label study. Arthritis Rheum. 2004;50:3161–3169
  46. Katz RS, Holt-Daly N, MacDonald PA. Frequent infusion reactions associated with infliximab treatment in patients with polyarthritis related to systemic lupus erythematosus. [abstract] Arthritis Rheum. 2003;48:S379
  47. Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther. 2008;10(1):202
  48. Carlson E, Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. 2003;48:1165–1166
  49. Mor A, Bingham C, Barisoni L, et al. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol. 2005;32:740–743
  50. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20:1400–1406
  51. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther. 2004;6:R535–R543
  52. US National Institutes of Health . TNF blockade with Remicade in Active Lupus Nephritis WHO class V (trial). Available from: http://www. clinicaltrials.gov/ct2/show/NCT00368264?term = infliximab+SLE&rank = 1
  53. US National Institutes of Health . Etanercept for the Treatment of Lupus Nephritis. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00447265?term = SLE+etanercept&rank = 1
  54. Llorente L, Richaud-Patin Y, García-Padilla C, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 2000;43(8):1790–1800
  55. Niewold T, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol. 2005;24:178–181
  56. Crow M, Kirou K, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity. 2003;36:481–490
  57. A Study to evaluate the safety and tolerability of multiple subcutaneous doses of MEDI 545 in patients with systemic lupus erythematosus. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00482989?term = MEDI+545+SLE&rank = 2
  58. Davidson A, Diamond B, Wofsy D, Daikh D. Block and trackle:CTLA4Ig takes on lupus. Lupus. 2005;14:197–203
  59. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science. 1994;265:1225–1227
  60. Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with ctla4ig and cyclophosphamide. J Immunol. 2001;166:2913–2916
  61. Daikh DI, Finck BK, Linsley PS, et al. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol. 1997;159:3104–3108
  62. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest. 1996;97:2063–2073
  63. Kalled SL, Cutler AH, Datta SK, Thomas DW. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol. 1998;160:2158–2165
  64. Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and descreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48(3):719–727
  65. Davis JC, Totoritis MC, Rosenberg J, et al. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001;8:95–101
  66. Kalunian KC, Davis JC, Merrill JT, et al., IDEC-131 Lupus Study Group  Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(12):3251–3258
  67. Jones DS, Hachmann JP, Osgood SA, et al. Conjugates of double stranded oligonucleotides with poly(ethylene glycol) and keyhole limpet hemocyanin: a model for treating systemic lupus erythematosus. Bioconjug Chem. 1994;5:390–399
  68. Weisman MH, Bluestein HO, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol. 1997;24:314–338
  69. Alarcón-Segovia D, Tumlin JA, Furie RA, et al., LJP 394 Investigator Consortium  LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2003;48(2):442–454
  70. Cardiel MH, Tumlin JÁ, Furie RA, et al., LPJ 394-90-09 Investigator Consortium  Abetimus sodium for renal flare in systemic lúpus erythematosus: results of a randomized, controled phase III trial. Arthritis Rheum. 2008;58(8):2470–2480
  71. US National Institutes of Health . Study of LJP 394 in Lupus patients with history of renal disease (ASPEN). Available from: http://www.clinicaltrials.gov/ct2/show/NCT00089804?term = abetimus+SLE&rank = 1
  72. Eilat E, Dayan M, Zinger H, Mozes E. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. Proc Natl Aca Sci USA. 2001;98(3):1148–1153
  73. Rapport MJ, Sharabi A, Aharoni D, et al. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin Immunol. 2005;117(3):262–270
  74. Elmann A, Sharabi A, Dayan M, et al. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations. Arthritis Rheum. 2007;56(7):2371–2381
  75. Teva pharmaceuticals . Available from: www.tevapharm.com/research/products_ai-asp
  76. Bao L, Osawe I, Puri T, et al. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol. 2005;35(8):2496–2506
  77. Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus. 2004;13:168–176
  78. Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA. 2006;295(5):527–535
  79. Isenberg DA, Gordon C, Merrill J, Urowitz M. New therapies in systemic lupus erythematosus - trials troubles and tribulations…working towards a solution. Lupus. 2008;17:967–970

PII: S1521-6942(08)00159-9

doi: 10.1016/j.berh.2008.12.006

Best Practice & Research Clinical Rheumatology
Volume 23, Issue 4 , Pages 563-574 , August 2009

Article Tools